Bottom line
What is PCRRX's expense ratio?
PCRRX's expense ratio is 1.28%, or about $128 a year on every $10,000 invested. That is more expensive than 74% of commodities funds we track (median 0.9%). It has no front-end sales load. Its expense ratio includes a 0.25% 12b-1 marketing fee.
Updated Jul 28, 2026
PCRRX fee table
| Net expense ratio | 1.28% |
|---|---|
| Gross expense ratio | 1.41% |
| Management fee | 0.74% |
| 12b-1 (distribution) fee | 0.25% |
| Other expenses | 0.29% |
| Acquired fund fees | 0.13% |
| Fee waiver / reimbursement | -0.13% |
| Max front-end sales load | 0% |
| Max deferred sales charge | 0% |
Source: Fund prospectus fee table, filed Jul 28, 2026
What PCRRX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| PCRRX | $130 | $433 | $759 | $1,680 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 1.28% expense ratio costs roughly $69,200 in lost growth, versus about $50,300 for the median commodities fund (0.9%).